A carregar...
Kinase Impaired BRAF Mutations Confer Lung Cancer Sensitivity to Dasatinib
During a clinical trial of the tyrosine kinase inhibitor dasatinib for advanced non–small cell lung cancer (NSCLC) one patient responded dramatically and remains cancer-free 4 years later. A comprehensive analysis of his tumor revealed a previously undescribed, kinase inactivating BRAF mutation ((Y4...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3836384/ https://ncbi.nlm.nih.gov/pubmed/22649091 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3003513 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|